Race Oncology Limited (ASX: RAC), a specialty pharmaceutical company, has disclosed its new “5 Path” clinical strategy for Bisantrene, its cancer drug. The strategy defines five new paths for the clinical development of the drug, that greatly expands its addressable market.
- These five strategies will reduce clinical development risk and target cancers beyond Acute Myeloid Leukaemia (AML);
- The company will continue to focus on the use of Bisantrene in treating AML but will pursue to introduce the drug earlier in the treatment pathway.
At AEST 12:59 PM, the stock was trading at $0.130 per share, no change from its previous close.